Literature DB >> 8098245

Illegitimate transcription of the phenylalanine hydroxylase gene in lymphocytes for identification of mutations in phenylketonuria.

V Abadie1, J Jaruzelska, S Lyonnet, P Millasseau, M Berthelon, F Rey, A Munnich, J Rey.   

Abstract

Taking advantage of the 'illegitimate' transcription of the phenylalanine hydroxylase (PAH) gene, we have been able to analyse the PAH cDNA sequence of hyperphenylalaninemic children in circulating lymphocytes. Using this approach, we have also identified 3 novel mutations in cDNA from liver and lymphocytes of two patients. One mutation, detected by the abnormal pattern of migration of an amplified fragment, is a C to T transition in the splice acceptor site of intron 10, which resulted in the skipping of exon 11 with the premature termination of RNA translation downstream from exon 12 (-3 IVS10). The other two mutations are missense mutations in exons 10 and 11 (respectively, L333F and E390G). The present study supports the view that circulating lymphocytes give easy access to PAH gene transcripts whose nucleotide sequence is identical to that reported in liver and therefore represent a useful tool for molecular genetic studies in phenylketonuria.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098245     DOI: 10.1093/hmg/2.1.31

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  2 in total

1.  Founder Effect of a c.828+3A>T Splice Site Mutation in Peripherin 2 (PRPH2) Causing Autosomal Dominant Retinal Dystrophies.

Authors:  Suma P Shankar; David G Birch; Richard S Ruiz; Dianna K Hughbanks-Wheaton; Lori S Sullivan; Sara J Bowne; Edwin M Stone; Stephen P Daiger
Journal:  JAMA Ophthalmol       Date:  2015-05       Impact factor: 7.389

2.  Unexpected inactivation of acceptor consensus splice sequence by a -3 C to T transition in intron 2 of the CFTR gene.

Authors:  T Bienvenu; D Hubert; N Fonknechten; D Dusser; J C Kaplan; C Beldjord
Journal:  Hum Genet       Date:  1994-07       Impact factor: 4.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.